Immunotherapy of Hepatocellular Carcinoma
Springer International Publishing (Verlag)
978-3-319-87911-6 (ISBN)
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer.
Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Professor Tim F. Greten has received his training in Gastroenterology, Hepatology and Medical Oncology. He has been treating patients with hepatocellular carcinoma (HCC) for many years has been leading a number of clinical trials. Apart from his clinical expertise Professor Greten has been interested in the immunological aspects of HCC for more than 20 years. He is conducting basic research studies, which he published in the very top scientific journals including Nature, and Cancer Cell and is also a pioneer in immunotherapy studies in HCC. He published a number of different clinical trials testing different immune based approaches in HCC. Based on this medical and basic science background is considered on the world leaders in tumor immunology and immunotherapy of HCC.
lt;p>Introduction:
Tim F. Greten NCI, Bethesda,USA
1. Vaccine approaches
Luigi Buonagro, Naples, Italy
2. NK cell response in Hepatocellular Carcinoma
Gabriele Missale, Parma, Italy
3. Antigen-specific T cell responses in HCC
Shuichi Kaneko, Kanazawa, Japan
4. Immune checkpoint inhibitors for the treatment of HCC
Bruno Sangro, Nevarra, Spain
5. Cytokine activated killer cells for the treatment of patients with HCC
Jung-Hwan Yoon, Seoul, Korea
6. Sorafenib as a partner for immune based therapy approaches in HCC
Dan Duda, Harvard, Boston, USA
7. Glypican 3 as a target for immune based therapies in HCC
Mitchel Ho, NCI, Bethesda, USA
8. Suppressor cells and mechanisms in HCC
Tim Greten and Firouzeh Korangy, NCI, Bethesda,USA
9. Cytokines in alcoholic liver disease and HCC
Faoud Lafdil and Bin Gao
Index
| Erscheint lt. Verlag | 22.8.2018 |
|---|---|
| Zusatzinfo | X, 167 p. 19 illus., 15 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 384 g |
| Themenwelt | Medizin / Pharmazie ► Studium |
| Schlagworte | hepatocellular carcinoma • Immune-based treatment • immunotherapy • Liver Cancer • tumor immunology |
| ISBN-10 | 3-319-87911-1 / 3319879111 |
| ISBN-13 | 978-3-319-87911-6 / 9783319879116 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
